Journals / Haseki Tıp Bülteni / 2017 / Cilt: 55 - Sayı: 1

Congenital Chylothorax in a Newborn with Down Syndrome

Down Sendromlu Bir Yenidoğanda Konjenital Şilotoraks

Pages
74–77
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this report, a case of congenital chylothorax, in a newborn with Down syndrome, treated by octreotide after failure of chest tube drainage and medical treatment (total parenteral nutrition and medium chain fatty acid formula) is presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In the neonatal period, the most common cause of pleural effusion is idiopathic congenital chylothorax.
📊
Key Findings & Data:Congenital chylothorax is rarely associated with chromosomal abnormalities, such as Down, Turner and Noonan syndromes.
💡
Conclusion & Impact:In this report, a case of congenital chylothorax, in a newborn with Down syndrome, treated by octreotide after failure of chest tube drainage and medical treatment (total parenteral nutrition and medium chain fatty acid formula) is presented.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In the neonatal period, the most common cause of pleural effusion is idiopathic congenital chylothorax. Congenital chylothorax is rarely associated with chromosomal abnormalities, such as Down, Turner and Noonan syndromes. The diagnosis can be made after analysis of the pleural fluid drained by thoracentesis or chest tube placement. During the neonatal period, chylothorax treatment is composed of conservative and surgical therapies. Nowadays, for cases among which conservative therapies fail, treatment with octreotide has been reported to be beneficial with promising results. In this report, a case of congenital chylothorax, in a newborn with Down syndrome, treated by octreotide after failure of chest tube drainage and medical treatment (total parenteral nutrition and medium chain fatty acid formula) is presented.

Özet

Yenidoğan döneminde saptanan plevral efüzyonun en sık nedeni etiyolojisi bilinmeyen (idiyopatik) konjenital şilotoraksdır. Konjenital şilotoraks nadiren kromozomal anomalilerle (Down, Turner ve Noonan sendromları) birlikte olabilir. Tanı plevral efüzyonun torasentez veya toraks tüpü ile boşaltılarak analiz edilmesiyle konulur. Yenidoğan döneminde şilotoraks tedavisinde konservatif yaklaşımlar ve cerrahi yöntemler kullanılmaktadır. Günümüzde konservatif yaklaşımlara yanıt vermeyen olgularda, oktreotid tedavisi ile başarılı sonuçlar alındığı bildirilmektedir. Bu yazıda toraks tüpü ile drenaja ek olarak medikal tedaviye (total parenteral nütrisyon ve orta zincirli yağ asiti içeren formül mama) yanıt alınamayan ve oktreotid ile tedavi edilen Down sendromlu bir konjenital şilotoraks olgusu sunulmuştur.

🔖

Cite This Article

DOĞAN, N. N., DİLLİ, D., DİNLEN, N. F., ERDOĞAN, D., KOYUNCU, E., ZENCİROĞLU, A., KARAMAN, A., OKUMUŞ, N. (2017). Congenital Chylothorax in a Newborn with Down Syndrome. Haseki Tıp Bülteni, Cilt: 55 - Sayı: 1, 74–77. https://ajindex.com/articles/204150

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Tutor JD. Chylothorax in infants and children. Pediatrics 2014;133:722-33
  2. Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. Cochrane Database Syst Rev 2010:CD006388
  3. Paramés F, Freitas I, Fragata J, Trigo C, Pinto MF. Octreotideadditional conservative therapy for postoperative chylothorax in congenital heart disease. Rev Port Cardiol 2009;28:799- 807
  4. Bulbul A, Okan F, Nuhoglu A. Idiopathic congenital chylothorax presented with severe hydrops and treated with octreotide in term newborn. J Matern Fetal Neonatal Med 2009;22:1197- 200
  5. Hagay Z, Reece A, Roberts A, Hobbins JC. Isolated fetal pleural effusion: a prenatal management dilemma. Obstet Gynecol 1993;81:147-52
  6. Yoss BS, Lipsitz PJ. Chylothorax in two mongoloid infants. Clin Genet 1977;12:357-60
  7. Sepulveda W, Be C, Schnapp C, Roy M, Wimalasundera R. Second-trimester sonographic findings in trisomy 22: report of 3 cases and review of the literature. J Ultrasound Med 2003;22:1271-5
  8. Soto-Martinez M, Massie J. Chylothorax: Diagnosis and management in children. Paediatr Respir Rev 2009;10:199- 207
  9. Kovacikova L, Lakomy M, Skrak P, Cingelova D. Immunologic status in pediatric cardiosurgical patients with chylothorax. Bratisl Lek Listy 2007;108:3-6
  10. Goyal A, Smith NP, Jesudason EC, Kerr S, Losty PD. Octreotide for treatment of chylothorax after repair of congenital diahragmatic hernia. J Pediatr Surg 2003;38:19-20
  11. Uettiker V, Hug MI, Burger R, Baenziger O. Somatostatin: a new therapeutic option for the treatment of chylothorax. Intensive Care Med 2001;27:1083-6
  12. Kalomenidis I. Octreotide and chylothorax. Curr Opin Pulm Med 2006;12:264-7
  13. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J Ther 2001;8:409-15
  14. Zanin A, Padalino MA, Cerutti A, et al. Surgical ligation of cisterna chyli: An alternative treatment for chronic chylothorax in children. Ann Thorac Surg 2010;90:1732-4
  15. Shah D, Sinn JK. Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series. Acta Paediatr 2012;101:151-5